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Introduction. 18F-FDG-PET-CT plays an important role in the management of lymphoma postchemotherapy followup. Some
centres perform prechemotherapy baseline CT and postchemotherapy PETCT. With a concern of radiation burden, especially
in young patients, this study aimed to assess if PETCT radiation dose could be reduced. Methods. Retrospective analysis of
100 lymphoma patients was performed to record sites of disease on prechemotherapy CT and postchemotherapy PETCT. The
potential reduction in radiation and time achieved with PETCT limited to sites of known disease identiﬁed on prechemotherapy
CT was calculated. Results. No FDG-uptake was seen in 72 cases. FDG uptake at known disease sites was seen in 24. Of the
remaining 4, one had clinically signiﬁcant pathology, a rectal adenocarcinoma. PETCT did not reveal any unexpected sites
of lymphoma. Limiting PETCT to sites of known disease would have saved a mean radiation dose of 4mSv (27.3%), with a
mean time of 16minutes. Conclusion. Our study suggests that young patients may beneﬁt from reduced radiation by limiting
PETCT to sites of known disease with low risk of missing signiﬁcant pathology. However, in older patients, with increased
incidence of asymptomatic synchronous malignancies, whole-body PETCT is advisable unless prechemotherapy PETCT has been
performed.
1.Introduction
18F-Fluro-deoxyglucose positron emission tomography and
computed tomography (PET-CT) is a powerful imaging tool
for assessing response to chemotherapy in lymphoma pa-
tients. PETCT can accurately distinguish residual disease
from sequelae of treatment in postchemotherapy lesions [1–
13]. However, many lymphoma patients are young, and re-
peated exposure to ionising radiation during their patient
journey can lead to secondary cancers in later life [14]. It is
widely acknowledged that radiation dose should be kept as
low as reasonably practicable, whilst ensuring imaging pro-
tocolsareoptimised toensureeﬃcacyofdiagnostic informa-
tion [15, 16]. This study aims to assess whether PETCT from
skull base to pubic symphysis is feasible for assessing res-
ponse to chemotherapy in lymphoma patients, and to calcu-
latepossibleradiation doseandscan-timereductionsachiev-
able with a limited PETCT protocol.
2.MaterialsandMethods
2.1. Database. Local ethical board approval was obtained for
review and publication of data. Our cohort consisting of 100
subjects (55 males, 45 females) had an age range of 9 to 78
years with a mean of 41.7 years (56 patients were 45 years or
younger). 50 patients were identiﬁed with Hodgkin’s lym-
phoma (HL)and50 patients with non-Hodgkin’s lymphoma
(NHL). The distribution of the disease sites on the pre-
chemotherapy CT studies is shown in Table 1.
The chemotherapy regime varied depending on the type
of lymphoma. 83 of the 100 patients (83%) had received 6
cycles or more of chemotherapy prior to PETCT. All 100 pa-
tients (100%) had been assessed prior to chemotherapy with
diagnostic CT. Most CTs were performed at hospitals remote
from our institution and reported by consultant radiologists
atthosehospitals.ReportsfortheseCTswereavailableforre-
view. Sites of disease on prechemotherapy CT were grouped2 The Scientiﬁc World Journal
Table 1: Sites of disease at presentation on prechemotherapy CT.
For the disease sites, the “neck” includes supraclavicular fossae, and
the “chest” includes axillae.
Number of
disease
sites
Number of
patients
Sites of disease on prechemotherapy CT
16 0
Neck 6
Chest 33
Abdomen 19
Pelvis 2
2 30
Neck and chest 15
Chest and abdomen 11
Other 4
3 9
N e c k ,c h e s t ,a b d o m e n 5
Chest, abdomen, pelvis 3
N e c k ,c h e s t ,p e l v i s 1
41 Neck, chest, abdomen, and pelvis 1
into four categories: (A) disease in the neck (including supr-
aclavicular fossae, SCF), (B) disease in the chest (including
axillae), (C) disease in the abdomen, and (D) disease in the
pelvis.
2.2. PETCT. All patients were imaged with a discovery ST
(GE Medical Systems, Waukesha, Wisconsin) PETCT post-
chemotherapyusingourstandardwhole-bodyscanprotocol.
The PET enabled simultaneous acquisition of 47 transverse
PET images per ﬁeld of view with intersection spacing of
3.27mm. The ﬁeld of view and pixel size of the PET images
reconstructed for fusion were 60cm and 4.7,mm respective-
ly, with a matrix size of 128 by 128. The scanner included a
four-detector row spiral CT with the following routine imag-
ing parameters: detector row conﬁguration 4 × 2.5mm,
pitch 1.5, table speed 15mm per gantry rotation, and rota-
tion time 0.8sec.
After a six-hour fasting period, patients were injected
with 4.5 MBq/kg body weight of FDG. Blood glucose levels
were checked before injection. Following 60 ± 5m i n u t e so f
uptake period, time during which the patient was instructed
torestwithouttalkingorchewing,datawasacquired.CTwas
performed from skull base to pelvis by performing a scout
view using 10mA and 120 kVp scanning parameters, follow-
ed by a spiral CT with 80mA, 140 kVp. No intravenous con-
trast was administered, and water was used to delineate
bowel. On completion of CT, 2D PET emission data (4 min-
utesperbedpositioncoveringanaxialFOVof15.7cmwitha
3-slice overlap) was obtained. The total acquisition time var-
ied between 25 and 30 minutes per patient. CT data was used
for attenuation correction. Data was displayed on a worksta-
tion (Xeleris, GE Medical Systems) for analysis.
2.3. Image Interpretation and Data Analysis. PETCT studies
were visually assessed on the manufacturer’s proprietary
viewing workstations by one experienced observer trained in
diagnostic radiology and nuclear medicine and with 20 years
experience of PET (WLW). All postchemotherapy PETCT
reports were reviewed by one investigator (TM), unaware of
otherimaging/clinicalﬁndingsorﬁnaloutcomeandanysites
of possible disease not already identiﬁed on the prechemo-
therapy CT were recorded. All patients with unexpected sites
of FDG uptake were sent questionnaires to obtain relevant
patient information that included subsequent investigations,
ﬁnal outcome, and period of followup. Case notes were re-
viewed, and when relevant, the prechemotherapy CTs were
reviewed.
2.4. Radiation Dose. The total eﬀective dose to the patient
was calculated, incorporating both PET and CT contribu-
tions from the postchemotherapy PETCT scan. In the case
of PET, absorbed doses per unit activity of 18F-FDG admin-
istered to organs or tissues are as reported in Publication 80
of the International Commission on Radiological Protection
(ICRP) [17]. Publication 80 of the ICRP uses tissue-weight-
ing factors to derive eﬀective doses per unit-injected activity
that are sensitive to the subject’s age. In the case of CT, the
widely used ImPACT patient dosimetry software calculator
(version 0.99s) was used to calculate the CT dose for each
individual patient [18]. To optimise results, patient-speciﬁc
details and scanner-speciﬁc parameters were considered in
the calculations. Furthermore, we modiﬁed the tube current
setting on the dose calculator from 80mA to 120mA for pa-
tients over 100kg to reﬂect our routine clinical protocols and
to facilitate more accurate results in obese patients. In each
subject, the eﬀective dose from the actual PETCT scan and
theeﬀectivedoseifonlyknowndiseasesiteshadbeenimaged
on the PETCT study were calculated.
3. Results
OnreviewofPETCTreports, 72patients hadnoFDGuptake
to suggest residual disease. Twenty-four patients had FDG
uptake consistent with active disease on PETCT in areas
where disease was seen on prechemotherapy CT. Four pa-
tients were identiﬁed to have FDG uptake in areas where dis-
ease had not previously been identiﬁed on prechemotherapy
CT. Two of these subjects presented with mild FDG uptake
in the paranasal sinuses, conﬁrmed as sinusitis on followup.
In one patient, a 9mm pulmonary nodule with a maximum
standardised uptake value (SUVmax) of 3.1 was observed.
Review of the prechemotherapy CT revealed that the nodule
waspresentbuthadnotbeenreported.Thenoduleremained
unchanged in size over the course of the following year. In
the fourth case, the scan of a 55-year-old man highlighted a
small area of intense FDG uptake in the rectum, proven by
sigmoidoscopy and biopsy to represent a small rectal adeno-
carcinoma.
No patient had new, undiagnosed sites of lymphoma
on PETCT outside those areas of disease established on the
prechemotherapy CT.
3.1. Reduction in Radiation Dose and Scanning Time. In our
patient cohort, the eﬀective dose per unit-injected activity
was 1.9E-2 mSv/MBq and 2.5E-02 mSv/MBq for adults and
10–15 for year olds, respectively, [17]. The mean (±SD)The Scientiﬁc World Journal 3
eﬀective dose (ED) for whole-body PETCT was 14.6 (±1.9)
mSv. The calculated mean (±SD) ED for a hypothetical scan
limited to the sites of disease seen on the prechemotherapy
CT was 10.6 (±2.2) mSv. This represents a mean % dose
savingof47.9%ontheCTcomponentofPETCTandamean
dose saving of 27.3% on the whole PETCT study. By limiting
PETCT studies to sites of known disease, the number of bed
positions scanned would have been reduced from a mean of
6 to 2 with a resultant mean saving of 16 minutes per patient.
4. Discussion
ThisstudyshowsthatlimitedPETCThaspotentialtobeused
for the assessment of residual disease in lymphoma without
compromise to the accuracy of the investigation. It has dual
advantages of reducing radiation exposure to the patient and
shortening scanning time.
The risk of developing a radiation-induced cancer has
been estimated at 5% per Sv in the general population but
is higher in younger patients [19] and as high as 15% per Sv
intheﬁrstdecadeoflife[14].Thisequatestoanapproximate
risk between 0.5 and 1 in 1000 for an exposure of 10mSv. In
addition, genetic defects caused by radiation may contribute
to the risk of cancer developing in descendants from these
patients [20]. Lymphoma patients generally undergo multi-
ple radiographic examinations during their patient journey
leading to signiﬁcant cumulative radiation doses to individ-
uals, and PETCT can be a relatively high radiation dose ex-
amination. Our study estimated that patients received a
mean eﬀective dose of 14.6mSv per standard PETCT scan
comprising 8.3mSv from CT and 6.3mSv from PET. This is
of concern as lymphoma often occurs in the young with a
long life expectancy, and those subjected to high radiation
dose have a signiﬁcant chance of developing radiation-in-
duced cancer [16].
However, in our study, limiting PETCT to sites of known
disease would have led to a mean percentage reduction in
radiation dose of 47% on the CT component and 27.3% on
the whole PETCT study.
Therearelimitations tothisstudy. Thesamplesizein this
retrospective study was relatively small, and we observed no
cases of lymphomas in unexpected sites on postchemother-
apy PETCT. This means that caution has to be applied when
extrapolating the data to lymphoma patients in general. Ide-
ally, we would like to compare pre- and postchemotherapy
PETCTs so that true speciﬁcity and sensitivity would be de-
termined. Prechemotherapy PETCT would also identify the
CT-negative PET-positive incidental lesions so that the lim-
itedpostchemotherapyPETCTwouldnotmisstheregionsof
interest.
Another limitation to this study was the inability of our
scanner to optimise CT dose within an individual PET FOV
containing the lesion. Irrespective of the location of a lesion,
our scanner was conﬁgured to scan integer multiples of the
15.7cm axial PET FOV rather than a limited section of this
FOV. This represented a drawback to dose optimisation, as
anentireFOVrequiredmoreCTdoseforattenuationcorrec-
tion compared with scanning a limited section of the FOV.
For current scanners, similar to ours, where the CT range is
deﬁnedasintegermultiplesoftheaxialFOVinthePETscan-
ner, this may lead to increased eﬀective dose compared with
the ideal case where a limited FOV may be imaged. Clearly in
the future, this dose issue will be optimized for scanners de-
veloped with continuous bed motion in the PET acquisition
[21] and generally for noncongruent imaging ranges in PET
and CT scans.
An incidental small rectal adenocarcinoma was detected
in a 55-year-old man. Agress and cooper reviewed 1750 pa-
tients whose PET scans revealed 30 unexpected histopatho-
logically conﬁrmed malignant or premalignant tumours.
This is not an inconsiderable number, but the mean age of
these patients was 69 years (range 46–87) [20]. We therefore
speculatethatinyoungerpatientstheriskofmissingasecond
pathology on a limited PETCT may well not be outweighed
by the extra radiation dose required. The optimal cut-oﬀ age
has yet to be determined.
The estimation of change in radiation dosage is related to
the number of sites of disease. Estimated mean reductions in
exposure and imaging time are based on a cohort in which
60% of the patients had disease limited to one site and
90% had disease limited to 2 sites. These results would be
diﬀerent with a diﬀerent population of lymphoma patients.
Dose calculations were based on disease sites identiﬁed on
prechemotherapy CT. PETCT is more sensitive for detecting
lymphoma,andsoitwouldbeexpectedthatinsomepatients
there would be sites of disease that would not have been
identiﬁed on the prechemotherapy CT. In our study, no sites
of lymphoma were detected on PETCT that had not already
been established on the prechemotherapy CT. There are two
possible reasons for this. It may be that by chance all sites of
lymphoma were detected on PETCT that had already been
established on the prechemotherapy CT. The more likely
reason is that there were foci of disease not identiﬁed on the
prechemotherapy CT, but these were also not recognised on
postchemotherapy PETCT because both occult and visible
diseases on CT had been treated; a diﬀerential response is
rare in lymphoma.
Nevertheless, despite these limitations, our study high-
lights the need to consider innovative PETCT protocols in
patients with lymphoma. This is especially important with
postchemotherapy studies as increasing numbers of lym-
phoma patients have baseline pretreatment PETCT which
should accurately delineate extent of lymphoma and identify
any incidental second pathology. Prospective studies, with
modiﬁed PETCT protocols to reduce radiation exposure, are
recommended. A further advantage of a limited PETCT is a
reduction in scanning time. This could potentially translate
into allowing more patients to be scanned and easing daily
scheduling of patients.
5. Conclusion
This study suggests that response to chemotherapy in
younger lymphoma patients is feasible using limited 18F-
FDG PETCT on sites of known disease, rather than perform-
ing full (“skull base to pubic symphysis”) scans. This limited4 The Scientiﬁc World Journal
18F-FDG PETCT would lead to an estimated mean reduction
toradiationdoseof4mSv(27.3%)perscanwithlittlechance
of missing signiﬁcant pathology. Using limited 18F-FDG
PETCT would also allow quicker scan times and make more
eﬃcient use of scanner resources.
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